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Abstract
Background: Epithelial ovarian cancer (EOC) is characterized by the overexpression of cancer antigen 125 (CA125),
a mucinous glycoprotein that serves as a tumor biomarker. Early diagnosis of EOC is plagued by its asymptomatic
nature of progression and the limitations of currently used immunoassay techniques that detect CA125 as a shed
antigen in serum samples. Presently, there is no technique available for the in vivo evaluation of CA125 expression
in malignant tissues. Moreover, there could be an unexplored pathophysiological time window for the detection of
CA125 in EOC, during which it is expressed on tumor cells prior to being shed into the bloodstream. A method for
the in vivo evaluation of CA125 expression on ovarian neoplasms earlier along disease progression and/or
recurrence can potentially contribute to better disease management. To this end, the present work utilizes an anti-CA125
monoclonal antibody (MAb) and a single-chain variable fragment (scFv) labeled with the positron-emitting radionuclide
64Cu for preclinical molecular imaging of CA125 expression in vivo.
Methods: Anti-CA125 MAb and scFv were prepared and functionally characterized for target binding prior to being
tested as radiotracers in a preclinical setting.
Results: Immunoblotting, immunofluorescence, and flow cytometry revealed specific binding of CA125-targeting vectors
to NIH:OVCAR-3 cells and no binding to antigen-negative SKOV3 cells. 64Cu-labeled anti-CA125 MAb and scFv
were obtained in specific activities of 296 and 122 MBq/mg, respectively. Both radioimmunoconjugate vectors
demonstrated highly selective binding to NIH:OVCAR-3 cells and virtually no binding to SKOV3 cells. In vivo
radiopharmacological evaluation using xenograft mouse models injected with 64Cu-labeled anti-CA125 MAb
provided a standardized uptake value (SUV) of 5.76 (29.70 %ID/g) in OVCAR3 tumors 24 h post-injection (p.i.)
versus 1.80 (5.91 %ID/g) in SKOV3 tumors. 64Cu-labeled anti-CA125 scFv provided an SUV of 0.64 (3.21 %ID/g) in
OVCAR3 tumors 24 h p.i. versus 0.25 (1.49 %ID/g) in SKOV3 tumors. Results from small-animal PET imaging were
confirmed by ex vivo autoradiography and immunohistochemistry.
Conclusions: Radiolabeling of anti-CA125 MAb and scFv with 64Cu did not compromise their immunoreactivity.
Both radioimmunoconjugates presented specific tumor uptake and expected biological clearance profiles. This
renders them as potential immuno-PET probes for targeted in vivo molecular imaging of CA125 in EOC.
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Background
Despite its relative rarity in the general population and the
availability of standard treatment through surgical inter-
vention and platinum chemotherapy, epithelial ovarian
cancer (EOC) continues to be the most insidious and le-
thal gynecologic malignancy in the western world. The
Surveillance Epidemiology and End Results (SEER) pro-
gram has estimated 21,980 new cases of ovarian cancer to
occur in 2014, with 14,270 deaths resulting from this dis-
ease in the United States alone [1]. A combination of the
asymptomatic nature of this malignancy and the high inci-
dence of recurrence results in a low 5-year survival rate of
44.6% [1].
Cancer antigen 125 (CA125) is a high molecular weight
mucinous glycoprotein overexpressed on the membrane
of EOC cells [2-4]. It has clinical relevance as a standard-
of-care serum biomarker for ovarian cancer surveillance
despite expression in some non-gynecologic malignancies
and benign conditions such as pregnancy, menstruation,
endometriosis, liver disease, and congestive heart failure
[3,4]. Post-treatment elevation of serum CA125 level in
EOC patients serves as an indicator of progressive disease
and finds clinical application in the management of pa-
tients with documented evidence of ovarian cancer [3-7].
However, a normal CA125 serum titer does not necessar-
ily imply an absence of the disease. This is exemplified by
the fact that an estimated 50% of patients with normal
levels of CA125 post-chemotherapy have small volumes of
active disease at second-look surgery, and a large portion
of this population succumbs to recurrence from the dis-
ease [5,6]. Presently, serial CA125 levels in patients are
evaluated using immunoassays.
However, despite their indicative utility, such assays
can be far from delivering a true representation of the
in vivo pathophysiological pattern and may be limited
in their capabilities for early detection of ovarian
neoplasms.
On a time scale of events for the diagnosis of recur-
rent ovarian cancer, it is known that radiological detec-
tion of the disease precedes the presentation of clinically
diagnosable symptoms by 2 to 3 months. Furthermore,
there is a median lag of 2 months between the elevation
of CA125 alone and the radiological detection of this
disease [5,6]. Among contemporary imaging modalities,
[18F] FDG-PET has shown the highest sensitivity and ac-
curacy in detecting recurrent ovarian cancer, while sim-
ultaneous investigations with CT, MRI, and ultrasound
which primarily detect morphological features and ana-
tomical changes that can be distorted on account of pri-
mary cyto-reductive surgery in patients yielded negative
or equivocal results [8-11].
Considering these facts, we hypothesized that a non-
invasive approach using targeted immuno-PET to dir-
ectly image the in vivo overexpression of CA125 on
epithelial ovarian neoplasms may detect the malignancy
at an earlier time, while providing a more accurate
in vivo evaluation of tumor load and residual disease.
Further, this approach could gain relevance when used
in a pathophysiological time window wherein CA125 ex-
pression is limited to the surface of ovarian neoplasms
prior to its shedding into the bloodstream. Our hypoth-
esis is strengthened further by a mathematical model
proposed by Hori and Gambhir [12] whereby an ovarian
tumor may grow for 10.6 years before attaining a size of
10.52 mm3 before it starts to shed just enough CA125
antigen (1.5 U/mL) detectable by immunoassay methods
used in the clinic.
Owing to its ability for targeting CA125 in ovarian can-
cer, MAb-B43.13 has been employed as an immunothera-
peutic agent in the treatment of EOC [13-15]. More
recently, immuno-PET has emerged as a strategy that uni-
fies the specificity of antibody-based targeting with the
sensitivity for detection imparted by positron-emitting ra-
dionuclides in PET in order to render a superlative diag-
nostic potential [16].
Findings from previous research with MAb-B43.13 and
more recent reports for antibody-based radiotracers tar-
geting biomarkers such as PSMA [17] and CA19-9 [18],
which have similar pathophysiological nature in prostate
and pancreatic cancers, respectively, motivated us to de-
velop an immuno-PET strategy for the in vivo imaging of
EOC. Additionally, we developed an antibody fragment of
MAb-B43.13, in order to produce a radiotracer that could
retain antigen-binding properties like the full-length anti-
body but achieve faster in vivo clearance and better tumor
penetration as a function of its smaller molecular size,
which may ultimately yield high-contrast in vivo PET im-
ages at earlier time points post-injection. To this end,
MAb-B43.13 and its derivative single-chain variable frag-
ment (scFv-B43.13) were labeled with positron emitter
64Cu (t1/2 12.7 h) and analyzed in vitro and in vivo using
CA125 overexpressing NIH:OVCAR-3 cells and CA125-
negative SKOV3 cells in preclinical EOC xenograft mouse
models.
Methods
Expression and purification of anti-CA125 MAb and scFv
The murine monoclonal IgG1 antibody targeting hu-
man CA125 was produced from hybridoma B43.13 [19]
that was kindly provided by Quest Pharma Tech Inc.,
Edmonton, Canada. The hybridoma cell culture super-
natant was used to purify the MAb-B43.13 by protein
G affinity (P-7700, Sigma-Aldrich, St. Louis, MO, USA)
on a BioLogic DuoFlow™ chromatography system (760–
0135, Bio-Rad Laboratories, Inc., Hercules, CA, USA).
MAb-B43.13-derived anti-CA125 scFv was produced with
modifications to previously described constructs [20,21].
Briefly, the DNA sequence encoding scFv-B43.13 was
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cloned into a pET22b + vector with a modified inter-chain
linker, and the protein was expressed in Escherichia
coli Rosetta 2 DE3 (Novagen, 71400–3, Merck KGaA,
Darmstadt, Germany). The C-terminal hexa-histidine-
tagged scFv was purified from the soluble fraction of
recombinant cell lysates by immobilized metal affinity
chromatography using a TALON® Superflow resin (635507,
Clontech Laboratories, Inc., Mountain View, CA, USA).
Cell lines and culture conditions
Ovarian cancer cell lines NIH:OVCAR-3 (ATCC® HTB-
161™, ATCC, Manassas, VA, USA) and SKOV3 (ATCC®
HTB-77™) were used for in vitro and in vivo studies. Cells
were cultured in DMEM-F12 medium supplemented with
10% v/v fetal bovine serum (FBS), 50 IU/mL penicillin,
and 50 μg/mL streptomycin (Gibco®, Life Technologies,
Carlsbad, CA, USA). NIH:OVCAR-3 cells were addition-
ally supplemented with 7 μg/mL recombinant human in-
sulin (91077C, SAFC Biosciences, Inc., Lenexa, KS, USA).
Cells were cultured using sterile techniques and grown in
a 37°C incubator providing humidified atmosphere of 5%
CO2 in air.
Characterization of CA125-targeting vectors
Western blotting
NIH:OVCAR-3 and SKOV3 cells (7.5 × 106) were lysed
with CelLytic™ M (C2978, Sigma-Aldrich). The cell lysates
were electrophoresed on a 4% to 15% Mini-PROTEAN®
TGX™ precast gel (456–1085, Bio-Rad) and transferred to
a Trans-Blot nitrocellulose membrane (162–0115, Bio-
Rad). The membranes were probed separately to evaluate
MAb versus scFv binding to the target antigen in cell ly-
sates. The blots were blocked for 45 min with 5% non-fat
dry milk (Carnation) in PBS having 0.1% Tween-20
(PBST). Anti-CA125 MAb (3 mg/mL), mouse anti-β actin
IgG (A1978, Sigma-Aldrich), and anti-CA125 scFv (3 mg/
mL) were used as primary antibodies to probe the blots at
1:5,000 dilutions for 1 h at room temperature. Goat
anti-mouse HRP conjugate (A4416, Sigma-Aldrich) was
used as secondary antibody to probe the blot against anti-
CA125 MAb and mouse anti-β actin IgG at 1:5,000 dilu-
tion for 1 h at room temperature. 6xHis MAb-HRP
conjugate (631210, Clontech) was used as secondary
antibody at 1:5,000 dilution to probe against anti-CA125
scFv for 1 h at room temperature. The blots were washed
with PBST and developed on Amersham Hyperfilm
ECL (28906839, GE Healthcare, Little Chalfont, UK)
using Amersham ECL Plus Western Blotting Detection
Reagents (RPN2132, GE Healthcare).
Fluorescent labeling of anti-CA125 MAb/scFv
One milligram each of anti-CA125 MAb and scFv at con-
centrations of 2 mg/mL were fluorescently labeled using
the Pierce® fluorescein isothiocyanate (FITC) antibody
labeling kit (53027, Thermo Scientific, Waltham, MA,
USA) according to the manufacturer's instructions.
Flow cytometry
NIH:OVCAR-3 cells (1.5 × 106) were harvested by trypsi-
nization, rinsed twice with fluorescence-activated cell
sorting (FACS) buffer (PBS with 0.5% heat-inactivated
FBS, 2 mM EDTA, 0.05% sodium azide), and re-
suspended by gentle tapping in an approximately 100 μl
FACS buffer. Ten micrograms of anti-CA125 MAb or
scFv was incubated with the cell suspension for 30 min
at room temperature. Cells were rinsed twice in FACS
buffer and incubated for 30 min with 4 μg of Alexa
Fluor® 488 goat anti-mouse antibody (A-11001, Life
Technologies) for the MAb samples and 4 μg of Penta ·
His Alexa Fluor 488 conjugate (35310, Qiagen, Venlo,
the Netherlands) for the scFv samples. Cells were rinsed
twice with FACS buffer and analyzed by flow cytometry
on a BD FACS Calibur (BD Biosciences, San Jose, CA,
USA). A dengue virus targeting IgG1-12A1 and a hexa-
histidine-tagged anti-RANK receptor binding scFv were
used as isotype controls for the experiments. Negative
controls included unstained NIH:OVCAR-3 cells and
cells incubated with Alexa Fluor 488 conjugated anti-
bodies alone.
Immunofluorescence
NIH:OVCAR-3 and SKOV3 cells were plated onto glass
coverslips in 35-mm tissue culture dishes (100,000 cells/
2 mL medium/dish) and incubated at 37°C for 48 h. The
cells were rinsed with PBS and fixed in methanol for
30 min at −20°C. The fixed cells were incubated in 5%
non-fat dry milk (Carnation) in PBS for 30 min and im-
munostained separately for 1 h with FITC-labeled versus
unlabeled anti-CA125 MAb and scFv. The unlabeled
MAb and scFv samples were indirectly stained with cor-
responding Alexa Fluor 488-labeled secondary anti-
bodies as used for flow cytometry experiments.
Anti-CA125 MAb and scFv (2 mg/mL) were used at
1:250 dilution followed by 1:500 dilutions of secondary
antibodies (2 mg/mL) in PBS containing 5% non-fat dry
milk. Appropriate blank and control samples were in-
cluded in the experiments. Antibody incubations were
followed by three rinses with PBST for 5 min each. Cov-
erslips were mounted on microscopy slides (Fisherbrand,
12-550-003, Thermo Fisher Scientific) using Mowiol®
mounting medium (Calbiochem, 475904, Millipore Co.,
Billerica, MA, USA) supplemented with DAPI (50 μg/
mL). Immunofluorescence was observed through a Zeiss
Plan Apochromat 40X/1.3 Oil DIC M27 lens on a con-
focal laser scanning microscope (Zeiss LSM 710, Carl
Zeiss AG, Oberkochen, Germany), and images were ana-
lyzed using Zen 2011 software. Separately, 30 μg of FITC-
labeled anti-CA125 MAb was added to NIH:OVCAR-3
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cells grown on coverslips and allowed to incubate under
standard cell culture conditions over a period of 48 h to
study uptake in live cells. Coverslips were washed and
mounted on glass slides for analysis by confocal micros-
copy at 0.5-, 1-, 4-, 12-, 24-, and 48-h time points.
Surface plasmon resonance
Kinetic constants for association (ka) and dissociation (kd)
and affinity constant KD for anti-CA125 MAb-B43.13 and
scFv-B43.13 were determined by surface plasmon res-
onance on a Biacore 3000 instrument (GE Life Sciences,
Piscataway, NJ, USA). Upon activation of a CM5 sensor
chip with a 1:1 mixture of N-hydroxysuccinimide/N-ethyl-
N′-(3-dimethylaminopropyl)-carbodiimide hydrochloride,
amine coupling of antigen-grade human ovarian cancer
native CA125 protein (MBS318371, MyBioSource, Inc.,
San Diego, CA, USA) dissolved in 10 mM sodium acetate
buffer pH 5.0 was performed to couple approximately
1,200 relative units. The remaining reactive groups in the
control and test lanes were inactivated using ethanolamine
from the amine coupling kit (GE Life Sciences). The bind-
ing of antibody vectors to CA125 immobilized on the
CM5 chip was assessed in duplicates across concentration
ranges between 18.7 nM and 9.33 μM for MAb-B43.13
and 19.6 nM and 19.6 μM for the scFv-B43.13, respect-
ively. Each sample of MAb/scFv in the aforementioned
concentrations in binding buffer (10 mM HEPES, pH 7.0)
was injected for 3 min at a flow rate of 30 μL/min to allow
binding with the antigen. The binding buffer was allowed
to flow over the sensor chip for 15 min at a rate of 30 μL/
min to allow for the dissociation of bound MAb/scFv
from the antigen on the chip. Next, the regeneration buf-
fer (10 mM HEPES pH 7.0 supplemented with 800 mM
KCl) was passed over the chip surface to achieve dissoci-
ation of any remaining bound analyte, followed by 2 min
for stabilization before the next injection. BIAcore control
software 3.2 was used to analyze the data, and the best 1:1
Langmuir binding fit was used to derive kinetic constants.
Preparation of CA125-targeting radioimmunoconjugates
General
All glassware was rinsed with ultra-pure HCl (Fisherbrand,
A508-P500, Thermo Fisher Scientific). Trace metal basis
ultra-pure chemicals for buffer preparations were pur-
chased from Sigma-Aldrich. All buffer solutions were




triazacyclononane-1,4,7-triacetic acid] (B-605, Macro-
cyclics, Dallas, TX, USA) was conjugated to anti-CA125
MAb and scFv to serve as a bifunctional chelator for 64Cu
radiolabeling. Briefly, a 6 M excess of p-SCN-Bn-NOTA
in DMSO was added to anti-CA125 MAb/scFv in
0.1 M sodium bicarbonate buffer pH 9.0 and allowed to
react for 1 h at 37°C. NOTA-functionalized anti-CA125
MAb/scFv was purified from excess unconjugated bi-
functional chelator while simultaneously achieving buf-
fer exchange into 0.25 M sodium acetate pH 5.5 by
using an Econo-Pac 10DG desalting column (732–2010,
Bio-Rad). Protein quantification of the column-eluted
fractions was performed using A280 measurements on
nanodrop 2000 (Thermo Scientific) and bicinchoninic
assay (Pierce BCA Protein Assay kit, 23227) using a Syn-
ergy H1 multimode microplate reader for A562 absorbance
read-out. The number of bifunctional chelates conjugated
per MAb and scFv was determined by matrix-assisted
laser desorption-ionization time-of-flight (MALDI-TOF)
MS analysis and according to the method described by
Cooper et al. [22]. The purified immunoconjugates were
used in radiolabeling experiments.
64Cu labeling of NOTA-functionalized MAb/scFv
64Cu was produced via a 64Ni(p, n)64Cu nuclear reaction on
a CS-15 biomedical cyclotron at Washington University, St.
Louis, USA as previously described [23] and supplied as
high specific activity 64CuCl2 in 0.1 N HCl. Ammonium
acetate (0.1 M; pH 5.5) was added to 64CuCl2 to form
64Cu-acetate 64Cu (OAc)2 solution. To 100 μg of NOTA-
functionalized MAb/scFv, 85 MBq of 64Cu (OAc)2 was
added and allowed to react on a thermomixer at 30°C,
550 rpm for 1 h. EDTA (1 mM) was added to quench the
reaction over 10 min. 64Cu-labeled MAb/scFv radioimmu-
noconjugates were purified on an Econo-Pac 10DG desalt-
ing column pre-equilibrated with 0.25 M sodium acetate,
pH 5.5 used as the eluant. Elution fractions (350 μL) were
collected from the column, and the radioactivity was mea-
sured using an Atomlab 400 dose calibrator (Biodex,
Shirley, NY, USA). Fifteen microliters of each elution frac-
tion was electrophoresed on a 12% SDS-PAGE gel under
non-reducing conditions and evaluated by autoradiography
on a BAS-5000 phosphorimager (Fujifilm, Tokyo, Japan).
Radiochemical yields and purity were determined by instant
thin layer chromatography on ITLC-SG (SGI001, Varian,
Inc., Palo Alto, CA, USA), using 10 mM EDTA pH 5.5 as
the eluant. Fractions containing high specific activity
radioimmunoconjugates were used for in vitro and in vivo
radiopharmacological experiments. Monoclonal IgG1 anti-
body 12A1 was modified into an immunoconjugate and
radiolabeled with 64Cu as described above to serve as a
non-specific isotype control for in vivo experiments.
Functional characterization of CA125-targeting
radioimmunoconjugates
Cell uptake studies
NIH:OVCAR-3 and SKOV3 cells were seeded to obtain
250,000 cells per well in 12-well tissue culture plates.
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Prior to the uptake experiment, the growth medium
was removed and cells were rinsed twice with PBS and
incubated in Krebs buffer at 37°C for 1 h. The radioim-
munoconjugate (100 KBq) was added to each well ex-
cept those assigned to measure background activity
alone. Cell uptake was terminated at 5, 10, 15, 30, 60, 90,
and 120 min by adding ice-cold Krebs buffer and rinsing
the wells twice to wash away any unbound radioimmuno-
conjugates prior to lysing the cells with RIPA buffer.
The cell lysates were transferred to scintillation vials and
measured for radioactivity using a γ-counter (Wizard2®
2480 Automatic Gamma Counter, PerkinElmer, Ontario,
Canada). Protein levels were quantified using a Pierce™
BCA protein assay kit according to the manufacturer's rec-
ommendations. Cell uptake levels were normalized to per-
centage of the total amount of radioactivity per milligram
of protein (% radioactivity/mg protein) and plotted as a
function of time. All experiments were performed in
triplicates.
Immunoreactivity of the radioimmunoconjugates was
assessed by cell binding assays according to the method
of Lindmo et al. [24].
In vivo experiments
Xenograft models All animal experiments were carried
out according to guidelines of the Canadian Council on
Animal Care (CCAC) and approved by the local animal
care committee of the Cross Cancer Institute. Six-week-
old BALB/c nude female mice were obtained from
Charles River labs (Quebec, Canada). The animals were
housed in ventilated cages and provided food and water
ad libitum. NIH:OVCAR-3 tumors were induced on the
left shoulder by two subcutaneous injections of 15 × 106
and 10 × 106 cells in a 300 μL suspension of 1:1 mixture
of PBS and Matrigel (354234, BD Biosciences). The sec-
ond injection of cells was administered at the same site
within 7 to 10 days. NIH:OVCAR-3 tumors grew for 6
to 8 weeks before reaching suitable tumor sizes of 150
to 200 mm3.
SKOV3 tumors were induced on the left shoulder by a
single subcutaneous injection of 5 × 106 cells in PBS and
were grown for about 2 to 3 weeks before achieving
similar tumor sizes.
Animal imaging
Small-animal PET experiments were performed on a
MicroPET® R4 or INVEON PET scanner (Siemens
Preclinical Solutions, Knoxville, TN, USA). Mice were
anesthetized by inhalation of isoflurane in 40% oxygen/
60% nitrogen, 1 L/min, while maintaining body tempe-
rature at 37°C throughout the experiment; 6 to 10 MBq of
high specific activity radioimmunoconjugate (approxi-
mately 30 to 40 μg) in 150 to 200 μL of 0.25 M sodium
acetate (pH 5.5) was administered intravenously via a tail
vein catheter. For blocking experiments, 1 mg of unmodi-
fied anti-CA125 MAb was administered intraperitoneally
24 h prior to injection of the 64Cu-labeled radioimmuno-
conjugates. In separate animals, 8 to 10 MBq of 64Cu-la-
beled 12A1 IgG1 was administered via tail vein injection
to evaluate non-specific uptake. Whole-body PET data
was acquired by performing static scans for each animal at
24 h post-injection (p.i.) and 48 h p.i. Data acquisition
continued for 60 min in 3D list mode. The image files
were reconstructed using the maximum a posteriori
(MAP) algorithm. The image files were further processed
using the ROVER v 2.0.51 software (ABX GmbH, Rade-
berg, Germany). Masks for defining 3D regions of interest
(ROI) were set, and the ROIs were defined by threshold-
ing. Standardized uptake values [SUV = (activity/mL
tissue)/(injected activity/body weight), mL g−1] were cal-
culated for each ROI. Additionally, radioactivity uptake
was also analyzed as percentage of injected dose per gram
tissue (%ID/g). Data are expressed as means ± SEM from
n investigated animals.
Ex vivo analyses
An NIH:OVCAR-3 tumor-bearing mouse was injected
with 4.55 MBq of 64Cu-labeled anti-CA125 MAb via the
tail vein. At 24 h p.i., the animal was euthanized by cer-
vical dislocation. The tumor was submerged into OCT
medium and flash frozen using a bath of dry ice-cooled
methanol. Seven-micrometer slices were cut on a Leica
CM 1850 cryostat (Leica Microsystems, Singapore).
Autoradiography
Tissue sections were placed into a BAS-Cassette (2325,
Fujifilm) and exposed to a phosphor imaging plate
(BAS-MS 2025, Fujifilm) for 15 h at room temperature.
The images were developed on a BAS-5000 reader (Fuji
Photo Film Co., Ltd.) and analyzed with Adaptive Image
Deconvolution Algorithm (AIDA) Image Analyzer v.450
software.
Immunofluorescence
Upon thawing, tissue sections were fixed with formalin
for 30 min. The fixed sections were blocked overnight at
4°C using 0.12 mg/mL unconjugated goat anti-mouse
Fab fragment (115-003-007, Jackson Immunoresearch,
West Grove, PA, USA) in 0.5% fish skin gelatin (G7765,
Sigma-Aldrich) pH 7.4, supplemented with 0.1% Triton
X-100. The sections were rinsed 3× with Tris-buffered
saline having 0.5% Tween 20 (TBST) for 5 min each.
MAb-B43.13 was used as primary antibody at a dilution
of 1:6,000 in Dako antibody diluent (S0809, Dako,
Glostrup, Denmark) and allowed to incubate overnight
at 4°C. The sections were rinsed 3× with TBST and in-
cubated with Alexa Fluor® 488 goat anti-mouse anti-
body (A-11001, Life Technologies) used as secondary
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antibody at 1:400 dilution in Dako antibody diluent
for 2 h at room temperature. After three washes with
TBST, the sections were rinsed with water and coun-
terstained using Hoechst H33342 (2 μg/mL) for 5 min.
The sections were rinsed and mounted under a cover-
slip using FluorSave (345789, Calbiochem). The slides
were analyzed with a Zeiss Plan Apochromat 10X/0.45
na lens on a confocal laser scanning microscope (Zeiss
LSM 710) using Z-stack for image acquisition. The
images were registered using Zen 2011 software
(Zeiss) and further processed with Adobe Photoshop
CS6.
Immunohistochemistry
To analyze the samples for immunohistochemistry, the
same procedures for treatment, fixation, blocking, and
probing of tissue with primary antibody were followed.
DakoEnVision™ +HRP-conjugated anti-mouse antibody
was used as a secondary antibody, and no counterstain
was employed. The sections were observed with a Zeiss
Fluar 2.5X/0.12 na lens on an Axioskop 2 Plus micro-
scope. Images were processed and analyzed on AxioVi-
sion 4.7 (Zeiss) and further processed with Adobe
Photoshop CS6.
Statistical analysis
All data are expressed as means ± SEM. Graphs were
constructed using GraphPad Prism 4.0 (GraphPad Soft-
ware). Where applicable, statistical differences were tested
by unpaired Student's t test and were considered signifi-
cant for p <0.05.
Results
Isolation, characterization, and modification of CA125-
targeting vectors
CA125-targeting vectors were purified in yields of 6 mg/L
for MAb-B43.13 and 0.7 mg/L for the scFv (Figure 1A).
Analysis by Western blot (Figure 1B) and immunofluores-
cence staining (Figure 2A) ascertained the following: a) ex-
pression of CA125 in NIH:OVCAR-3 cells, b) absence of
CA125 expression in SKOV3 cells, and c) binding of MAb
and scFv to target antigen CA125. Isothiocyanate-based
labeling of anti-CA125 MAb and scFv with fluorescein
yielded 2 mol of FITC per mole of MAb and scFv. SPR
analysis calculated an affinity constant of 2.56 × 10−9 M
for MAb-B43.13 and 1.11 × 10−8 M for the scFv, with
comparable dissociation constants in the range of 10−4 s−1
(Additional file 1: Table S1).
Immunofluorescence staining and flow cytometry ana-
lysis with the FITC-labeled MAb and scFv demonstrated
preserved immunoreactivity by binding to CA125 anti-
gen expressed on the membrane of NIH:OVCAR-3 cells,
and no binding was seen with SKOV3 cells (Figure 2A,
B, C).
FITC-labeled anti-CA125 MAb remained membrane
bound over a period of 48 h with minimal cellular in-
ternalization observed upon incubation with live NIH:
OVCAR-3 cells in culture (Figure 3).
Development and functional assessment of CA125-
targeting radioimmunoconjugates
MALDI-TOF analyses and isotopic dilution assays re-
vealed an average of 2.4 NOTA molecules conjugated
per MAb and 1.9 NOTA molecules conjugated per scFv
Figure 1 Representative images and Western blots. (A) Representative images of purified anti-CA125 MAb (148 KDa) and scFv (28 KDa) upon
SDS-PAGE under non-reducing conditions. (B) Western blots of SKOV3 (CA125−) and NIH:OVCAR-3 (CA125+) cells with anti-CA125 MAb, anti-β
actin antibody (left side of molecular weight marker); anti-CA125 scFv, and anti-β actin antibody (right side of molecular weight marker).
Sharma et al. EJNMMI Research 2014, 4:60 Page 6 of 13
http://www.ejnmmires.com/content/4/1/60
(Additional file 1: Figures S2 and S3). 64Cu-labeling and
purification of radioimmunoconjugates provided isolated
radiochemical yields of 65% ±8% (n = 14) with specific
activity of 296 ± 37 MBq/mg for anti-CA125 MAb and
56% ±14% (n = 9) with specific activity of 122 ±
44 MBq/mg for anti-CA125 scFv (Figure 4).
Radiochemical purity of the isolated radioimmuno-
conjugates was greater than 99% as analyzed by ITLC
(Additional file 1: Figure S4) and phosphor images of
electrophoresed fractions (Additional file 1: Figure S5).
Purified radioimmunoconjugates were >95% stable in
human AB-type serum over 48 h (Additional file 1:
Figures S6 and S7) and demonstrated highly specific
binding to CA125 expressed on NIH:OVCAR-3 cells
with virtually no binding to SKOV3 cells as evaluated
by cell uptake studies (Figure 5A, B). Immunoreactivity
of 64Cu-labeled anti-CA125 MAb and scFv preparations
was found to be >90% as obtained from the inverse of
the intercept of plots seen in Figure 5C, D, respectively.
In vivo experiments and radiopharmacological evaluation
PET imaging studies performed with 64Cu-labeled anti-
CA125 MAb and scFv in NIH:OVCAR-3 and SKOV-3
tumor-bearing mice as well as experiments with 64Cu-
labeled isotype IgG and [18F] FDG are summarized in
Figure 6.
In NIH:OVCAR-3 tumors, 64Cu-labeled anti-CA125
MAb reached a maximum SUVmean of 5.76 ± 0.85
(29.70 ± 3.34 %ID/g) at 24 h p.i. rising to 7.06 ± 0.67
(41.66 ± 4.38 %ID/g) at 48 h p.i. (n = 4). NIH:OVCAR-3
Figure 2 Confocal microscopy and flow cytometry. (A) Confocal microscopy images from immunofluorescence studies. (a-b) Immunostaining
of NIH:OVCAR-3 cells with unlabeled versus FITC-labeled anti-CA125 MAb. Goat anti-mouse Alexa Fluor 488 IgG (GAM-A488) was used as secondary
antibody. (c-d) Immunostaining of NIH:OVCAR-3 cells with unlabeled versus FITC-labeled anti-CA125 scFv. Penta-His Alexa Fluor 488 antibody was used
as secondary antibody. (e) Unstained NIH:OVCAR-3 cells - blank. (f) NIH:OVCAR-3 cells stained with GAM-A488 antibody - negative control. (g) NIH:
OVCAR-3 cells stained with Penta-His Alexa Fluor 488 antibody - negative control. (h) Immunostaining of NIH:OVCAR-3 cells with MAb 12A1
and GAM-A488 antibody - isotype control. (i-j) Immunostaining of SKOV3 cells with unlabeled versus FITC-labeled anti-CA125 MAb. (k-l) Immunostaining
of SKOV3 cells with unlabeled versus FITC-labeled anti-CA125 scFv. Scale bar represents 10 μm. Flow cytometry analysis of (B) anti-CA125 MAb and (C)
anti-CA125 scFv binding to NIH:OVCAR-3 cells.
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xenograft mice pre-dosed with unlabeled MAb revealed a
SUVmean of 2.90 ± 0.45 (13.10 ± 2.07 %ID/g) at 24 h p.i.
(n = 4, p <0.05) and 3.96 ± 0.76 (14.47 ± 3.01 %ID/g) at
48 h p.i. (n = 4, p <0.05). Non-specific tumor uptake using
64Cu-labeled isotype IgG1 was found to have a SUV-
mean of 1.77 ± 0.44 (9.77 ± 0.44 %ID/g) at 24 h p.i. (n = 3,
p <0.05) with no further change at 48 h p.i. A SUVmean
of 1.80 ± 0.69 (5.91 ± 3.31 %ID/g) 24 h p.i. (n = 5, p <0.01
vs. uptake in OVCAR3 24 h p.i.) was observed in SKOV3
tumors.
In contrast, PET studies using 64Cu-labeled anti-CA125
scFv in xenograft mice revealed a SUVmean of 0.64 ± 0.04
(3.21 ± 0.29 %ID/g) 24 h p.i. (n = 3) in NIH:OVCAR-3
tumors and 0.25 ± 0.11 (1.49 ± 0.68 %ID/g) (n = 3, p
<0.05) in SKOV3 tumors.
Overall, in vivo clearance of the radioimmunoconjugates
was evaluated from the heart (representing blood pool
content), liver, and kidneys (Additional file 1: Figure S8).
After 24 h, SUVmean in the heart and liver of xenograft
animals imaged with 64Cu-labeled anti-CA125 MAb was
found to be 2.40 ± 0.20 (12.61 ± 1.15 %ID/g) and 2.59 ±
0.20 (12.54 ± 1.67 %ID/g) (n = 4), respectively. SUVmean
in the kidneys of these animals was 1.64 ± 0.09 (10.35 ±
1.06 %ID/g).
In contrast, injection of 64Cu-labeled anti-CA125 scFv
led to a SUVmean (n = 3) of 0.31 ± 0.06 (1.55 ± 0.40 %ID/g)
Figure 3 Confocal microscopy images of NIH:OVCAR-3 cells directly immunostained with FITC-labeled anti-CA125 MAb over 48 h.
Figure 4 Schematic representation of 64Cu-labeling of NOTA conjugated anti-CA125 MAb and scFv.
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in the heart, 0.98 ± 0.11 (4.89 ± 0.89 %ID/g) in the liver, and
13.2 ± 1.2 (66.46 ± 9.20 %ID/g) in the kidneys after 24 h.
This information demonstrated the different in vivo clear-
ance profile between the full-length antibody and the
fragment.
Ex vivo analysis
The NIH:OVCAR-3 tumor tested positive for CA125 ex-
pression as seen from immunofluorescence and immuno-
histochemistry of tissue sections (Figure 7A, B, C, D, E, F).
Immunohistochemistry revealed necrotic and apop-
totic regions spanned by connective tissue in the tumor's
upper half. Overall, the lower half had more radioactive
hot spots, stained stronger for CA125 expression, and
had more vasculature surrounded by positively staining
tumor foci, which collectively formed pockets of high
signals. CA125 staining was observed on the surface of
neoplastic cells in the tumor. Hot spots representative of
in vivo targeting by the radiotracer as seen in autoradi-
ography of tumor slices correlated well with signals from
the other two techniques.
A good correlation of all three types of signals was ob-
served in regions of tumor foci interspersed with blood
vessels and/or supported by mouse connective tissue.
Discussion
EOC accounts for more than 90% of all ovarian carcin-
omas presented in the clinic, and 70% of these cases
are high-grade serous ovarian cancers (HGSOC) over-
expressing CA125 [25]. This offers a premise to target
CA125 for in vivo diagnosis of ovarian neoplasms.
Here, OVCAR3 human adenocarcinoma cells represen-
tative of HGSOCs and SKOV3 cells representative of
human clear cell ovarian carcinoma that do not express
CA125 were utilized in order to develop a robust pre-
clinical testing platform to validate CA125 expression
and targeting. Both the cell lines displayed consistent
biochemical characteristics across in vitro, in vivo, and
ex vivo analyses.
Unlike a previous report [26], we engineered MAb-
B43.13 using a standard bioconjugation strategy to
radiolabel it with 64Cu towards development of a CA125-
targeted radiotracer for immuno-PET. To the best of our
knowledge, this is the first systematic report of an
immuno-PET strategy for the in vivo targeting and im-
aging of CA125 in EOC. In contrast to OVCAR3 cells in
culture, we found the uptake of [18 F] FDG in OVCAR3
tumors to be relatively low (Figure 6F), due plausibly to
the cystic nature of ovarian tumors in vivo [27]. Thus, the
utility of a targeted radiotracer that binds to cell surface
Figure 5 Cell uptake and double inverse plots. Graphs for cell uptake of (A) 64Cu-labeled anti-CA125 MAb and (B) 64Cu-labeled anti-CA125
scFv in NIH:OVCAR-3 and SKOV3 cells. Representative double inverse plots from Lindmo assays performed with (C) 64Cu-labeled anti-CA125 MAb
and (D) 64Cu-labeled anti-CA125 scFv in NIH:OVCAR-3 cells.
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antigen may be more sensitive and efficient for the in vivo
delineation of EOC.
In the present work, an isothiocyanate-based biocon-
jugation of a fluorescent tag and a macrocyclic chelator
within prescribed molar ratios to the anti-CA125 MAb
and scFv followed by radiolabeling yielded consistent
results without compromising their immunoreactivity.
This approach offers a scope for labeling MAb-B43.13-
based CA125-targeting vectors with different radionu-
clides, fluorophores, and functional groups for use in
diverse imaging and therapeutic applications. Further-
more, based on indications from a previous report [28]
and our own observations for non-internalization of
surface antigen-bound MAb-B43.13 over 48 h as shown
in Figure 3, pre-targeting applications are currently be-
ing explored via conjugation of click components to the
anti-CA125 MAb-B43.13.
The present study with CA125-targeting MAb-B43.13
and its derivative scFv in preclinical ovarian cancer
models found a higher targeted tumor uptake of 64Cu-
NOTA-MAb-B43.13. Specificity of the observed in vivo
tumor uptake was validated by pre-dosing OVCAR3
xenograft animals with 1 mg of unmodified anti-CA125
MAb 24 h prior to injection of 64Cu-labeled anti-
CA125 MAb and scFv. The non-specific tumor uptake
observed in our study was attributed to an enhanced
permeability and retention effect (EPR) [29], whose nu-
merical value (SUV) fell in range with the uptake of
64Cu-NOTA-MAb B43.13 observed in CA125-negative
SKOV3 tumors.
The background radiation in all PET imaging studies
using 64Cu-NOTA-MAb B43.13 could be attributed to
a) its longer residency time in circulation, b) consistent
non-specific muscle uptake of the radiotracer in all ex-
perimental animals (Additional file 1: Figure S9), c)
hepatobiliary clearance of the radiotracer and its associ-
ated immunocomplexes, and d) potential in vivo trans-
chelation of 64Cu from NOTA by hepatic enzymes such
Figure 6 PET images and diagrams. (A-E, G-I) Representative 24-h post-injection small-animal-PET images of xenograft mice injected with
radioimmunoconjugates. (F) 1-h p.i. PET image of NIH:OVCAR-3 xenograft mouse injected with 18 F-FDG. Color intensity scale bars represent standardized
uptake value (SUV) of radiotracer in animals. Diagrams on the right show (J) SUV in tumors of experimental and control animals using 64Cu-labeled anti-
CA125 MAb, (K) SUV in NIH:OVCAR-3 tumors after correction for non-specific uptake, (L) tumor SUV obtained from injection of 64Cu-labeled anti-CA125
MAb in NIH:OVCAR-3 versus SKOV3 xenograft mice, and (M) tumor SUV obtained from injection of 64Cu-labeled anti-CA125 scFv in NIH:OVCAR-3 versus
SKOV3 xenograft mice. Numbers of animals (n) are indicated at the bottom of each bar.
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as superoxide dismutase (SOD). However, NOTA has
previously demonstrated high in vivo kinetic stability as
a chelator for 64Cu2+ ions [30], and our in vitro chal-
lenge experiments for 64Cu-NOTA-MAb B43.13 in the
presence of an excess of purified SOD showed negli-
gible trans-chelation (Additional file 1: Figure S10).
In contrast to its favorable in vitro targeting proper-
ties and proposed advantages, the 64Cu-NOTA-scFv-
B43.13 was less efficient in its role as a radiotracer for
in vivo targeting of CA125. These observations are sup-
ported by other reports from in vivo use of such mono-
meric antibody fragments [31,32]. Although the scFv is
expected to be renally cleared, we observed maximum
renal trapping of the radioimmunoconjugate as early as
1 h p.i. (Additional file 1: Figure S11). Such a first pass
effect precludes the scFv’s bioavailability for any sub-
stantial tumor accumulation at later time points, thus
accounting for the lower tumor uptake observed with
this vector. This has prompted us to engineer the scFv
into a diabody to achieve competitive avidity and better
in vivo performance.
Ex vivo analysis by digital autoradiography reflected
successful in vivo tumor accumulation of the 64Cu-
NOTA-MAb-B43.13, while immunohistochemistry pro-
vided a panoramic view of CA125 expression in the
tumor, indicating regions of high vascularity and stromal
components in the tumor architecture. The lower half of
the tumor was relatively rich in vasculature and formed
suitable sites for neoplastic growth that appeared as
densely stained tumor foci. Such vasculature also serves
as a route of entry for targeted radioimmunoconjugates
into the tumor. Most of the correlating signals from re-
sults between the three ex vivo techniques described in
this study seem localized with strong CA125 staining in
areas of dense vascular perfusion. This phenomenon
may be a result of the limited penetration of antibody
radioimmunoconjugates extravasating across blood ves-
sels that constitute the aberrant tumor vasculature. This
is exacerbated by the tumor's interstitial fluid pressure
that can further impede the transport of antibodies once
they are within the tumor along their pursuit to reach
target cells that express CA125 [33-35]. Furthermore,
Figure 7 Autoradiography, immunofluorescence, immunohistochemistry, and overlay images. (A) Autoradiography image from a section
of NIH:OVCAR-3 tumor indicating hot spots of in vivo targeting by 64Cu-labeled anti-CA125 MAb. (B) Immunofluorescence image of the same section
staining green in regions of CA125 expression (Alexa Fluor 488) and counterstained blue (Hoechst 33342) for nuclei. (C) Overlay of images (A) and (B) to
establish concurrence between signals from independent methods of ex vivo analysis to indicate CA125 expression and targeting.
(D) Autoradiography image from a separate section of NIH:OVCAR-3 tumor indicating hot spots of in vivo targeting by 64Cu-labeled anti-
CA125 MAb. (E) Immunohistochemistry image of corresponding tissue section. Intensity of staining is indicative of CA125 expression across
the sample. (F) Overlay of images (D) and (E) to establish concurrence between signals from independent methods of ex vivo analysis to
indicate CA125 expression and targeting.
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the shedding properties of CA125 may create reservoirs
of shed antigen within regions of high CA125 expression
surrounding the tumor vasculature. This may lead to
most of the radiotracer forming high molecular weight
immunocomplexes at such junctions that may eventually
be cleared via lymphatics.
Although the use of subcutaneous xenograft models of
ovarian cancer allowed for easy assessment of tumor
burden and an evaluation of the extent of tumor target-
ing, this advantage also contributes to being a limitation
of this study. The next phase of testing this strategy will
involve the use of alternative xenograft and/or transgenic
animal models that more closely represent human EOC
within the natural setting of the peritoneum, accompan-
ied with an inducible recurrence of the disease. However,
a drawback to using such a model would be the signal
observed from organs of clearance such as the liver and
kidneys that may conceal ovarian tumors, closer to these
organs in the peritoneal cavity.
A concurrence of in vitro, in vivo, and ex vivo data
taken from this preclinical proof-of-concept study rep-
resents an initial step towards investigating CA125 as a
suitable target for the in vivo imaging of EOC. Drawing
information from the present study and prior literature
reports [12,36-38], it can be speculated that there may
be a pathophysiological time interval between the over-
expression of CA125 antigen on the surface of ovarian
neoplasms and its subsequent shedding into the blood-
stream of subjects at high risk for EOC and in recur-
rence. This time interval could be an existing gap
between active small volume disease brewing to relapse
out of the peritoneum and the limitations of present-
day methods for its detection via CA125 immunoas-
says. Molecular imaging by immuno-PET may possibly
bridge this gap to achieve a timely detection of EOC for
better disease management.
Conclusions
In the work at hand, we have described the synthesis
and preclinical radiopharmacological evaluation of 64Cu-
labeled MAb-B43.13 and its derivative scFv for the PET
imaging of CA125 in EOC. This approach offers both an
opportunity for early detection of EOC in patients at high
risk and a method to monitor patients for recurrence, by
providing a non-invasive in vivo assessment of CA125 sta-
tus. A robust model system was developed for preclinical
testing, and antibody-based CA125-targeting radioimmu-
noconjugates were successfully produced with excellent
immunoreactivity. Overall, our findings suggest that the
more efficient tumor-targeting capabilities and favorable
radiopharmacological profiles of the full-length antibody
make it a suitable radiotracer for non-invasive in vivo
evaluation of CA125 in EOC.
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